Acquisition (Tables)

12 Months Ended

Dec. 31, 2012

Acquisition [Abstract]

Schedule Of Purchase Price Allocation

Cash consideration	$	24,578
SciClone shares of common stock at estimated fair value on closing date		31,530
Contingent consideration (earn-out) at estimated fair value		18,870
Total purchase price	$	74,978

Schedule of Recognized Identified Assets Acquired and Liabilities Assumed

Cash	$	3,322
Accounts receivable		4,827
Inventory		1,724
Prepaid and other assets		486
Property and equipment		80
Deferred tax assets		1,389
Intangible assets - promotion
and distribution contract rights		46,310
Goodwill		32,843
Deferred tax liabilities		(9,352)
Liabilities assumed		(6,651)
Total net assets acquired (Restated)	$	74,978

Schedule Of Changes In Goodwill

Balance at December 31, 2010	$	—
Goodwill for the acquisition of NovaMed		32,843
Translation adjustments		1,025
Balance at December 31, 2011 (Restated)	$	33,868
Translation adjustments		445
Balance at December 31, 2012	$	34,313

Schedule Of Pro Forma Information

	For the Year Ended December 31,
	2011
	Restated
	(Note 2)		2010
Total revenues	$	140,604	$	116,520
Net income	$	24,849	$	20,021
Basic net income per share	$	0.45	$	0.42
Diluted net income per share	$	0.43	$	0.41

Information Included In Consolidated Statement Of Operations Of Parent Company

	For the Year Ended December 31,
				2011
				Restated
	2012			(Note 2)
Total revenues	$	44,100	$	27,852
Net loss	$	(40,258)	$	(3,835)